Clinical Trial

Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)

Study acronym: PRODIGYN
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are: * Does advanced medical imaging predict survival? * Can advanced medical imaging improve radiotherapy target planning? * Are advanced medical imaging results associated with risk markers found in tumor tissue? Participants will * Undergo four additional imaging procedures, as compared to clinical routine examinations, two at baseline and two after three months. * Be subject to clinical follow-up for five years.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-02; most recent amendment 2024-12-10.
Status change: Not Yet Recruiting → Recruiting 2023-08-10
Trial Details
NCT Number NCT05855941
Lead Sponsor Region Västerbotten
Collaborators: Umeå University
Conditions Cervix Cancer, Endometrial Cancer, Epithelial Ovarian Cancer
Enrollment 120 participants
Start Date 2023-05-23
Primary Completion 2032-05 (estimated)
Study Completion 2032-05 (estimated)
Updated on ClinicalTrials.gov 2024-12-16